Overview
The lab combines virology and cell biology to understand virus-host cell interactions and develop antiviral therapies, expanding research into cancer and other human diseases. Part of the Molecular Genetic and Therapeutics in Virology and Oncology (MOVION) research group at the Rega Institute, KU Leuven.
In the news
- Another great milestone for the Daelemans lab! We're excited to share our latest publication in 𝘕𝘢𝘵𝘶𝘳𝘦 𝘊𝘰𝘮𝘮𝘶𝘯𝘪𝘤𝘢𝘵𝘪𝘰𝘯𝘴: “𝐏𝐫𝐞𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐜𝐡𝐚𝐫𝐚𝐜𝐭𝐞𝐫𝐢𝐳𝐚𝐭𝐢𝐨𝐧 𝐨𝐟 𝐚 𝐫𝐞𝐯𝐞𝐫𝐬𝐢𝐛𝐥𝐞 𝐗𝐏𝐎1 𝐢𝐧𝐡𝐢𝐛𝐢𝐭𝐨𝐫 𝐟𝐨𝐫 𝐜𝐚𝐧𝐜𝐞𝐫 𝐭𝐡𝐞𝐫𝐚𝐩𝐲” Exportin 1 (XPO1) is a clinically validated anticancer target that plays a key role in transporting proteins from the nucleus to the cytoplasm. Inhibiting XPO1 can trigger cancer cell death, but currently available inhibitors are often associated
- We are excited to share our latest research, published in 𝘔𝘰𝘭𝘦𝘤𝘶𝘭𝘢𝘳 𝘛𝘩𝘦𝘳𝘢𝘱𝘺 𝘖𝘯𝘤𝘰𝘭𝘰𝘨𝘺: "𝐂𝐨𝐦𝐩𝐚𝐫𝐚𝐭𝐢𝐯𝐞 𝐞𝐯𝐚𝐥𝐮𝐚𝐭𝐢𝐨𝐧 𝐨𝐟 𝐨𝐧𝐜𝐨𝐥𝐲𝐭𝐢𝐜 𝐯𝐢𝐫𝐮𝐬𝐞𝐬 𝐫𝐞𝐯𝐞𝐚𝐥𝐬 𝐨𝐩𝐩𝐨𝐬𝐢𝐧𝐠 𝐩𝐫𝐞𝐟𝐞𝐫𝐞𝐧𝐜𝐞𝐬 𝐟𝐨𝐫 𝐠𝐥𝐢𝐨𝐛𝐥𝐚𝐬𝐭𝐨𝐦𝐚 𝐬𝐮𝐛𝐭𝐲𝐩𝐞𝐬" Glioblastoma is the most aggressive primary brain tumor in adults and remains extremely difficult to treat. Oncolytic viruses, viruses that selectively infect and kill cancer cells while stimulating an anti-tumor immune response, are
- Congratulations to our two newly graduated PhDs on the successful defense of their doctoral research! Over the past years, they have made important contributions to cancer research through very different approaches. Bert Kwanten applied CRISPR-Cas screening to identify determinants of cancer drug response, while Janne Van Hauwenhuyse investigated novel therapeutic strategies to battle glioblastoma. We are incredibly proud of their achievements and are excited to see what the future holds for them. #PhDDefense #CancerResearch
Related profiles
Something wrong or missing? Send an update. Fixed within 24 hours.